{"id":62064,"date":"2025-10-21T19:06:19","date_gmt":"2025-10-21T17:06:19","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\/"},"modified":"2025-10-21T19:06:19","modified_gmt":"2025-10-21T17:06:19","slug":"abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\/","title":{"rendered":"ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis"},"content":{"rendered":"
\n

\nA Global Turning Point for Critical Care Medicine<\/b><\/p>\n

TOULOUSE, France & FULLERTON, Calif.–(BUSINESS WIRE)–ABIONYX Pharma<\/b>, (FR0012616852 – ABNX – PEA PME eligible)<\/b>, a new generation biotech company dedicated to the world’s only recombinant apoA-I, today announced the publication of a ground breaking study in Scientific Reports<\/i> in Nature Portfolio titled \u201cPlasma apolipoprotein A-I is a causal protective factor in sepsis.\u201d<\/i> (https:\/\/www.nature.com\/articles\/s41598-025-19204-2#auth-Keith_R_-Walley-Aff1<\/a>)<\/p>\n

\nThis landmark publication provides, for the first time, genetic proof of a causal linkage between higher plasma ApoA-I levels and a lower incidence of sepsis and lower mortality in patients who do develop sepsis. At the same time, the publication provides genetic validation of the well-studied mechanism of apoA-I\u2019s beneficial impact on sepsis \u2013 the sequestration of the bacterial lipid toxin, LPS, which is responsible for the manifestations of sepsis. The report provides evidence that apoA-I is also effective in reducing mortality in Gram positive sepsis driven by the bacterial toxin lipoteichoic acid. Importantly, the findings were replicated across three independent data sets, including both Caucasian and Asian sepsis sufferers. The structural protein which defines HDL is apoA-I.<\/p>\n

\nThe study analyzed 442,601 participants from the UK Biobank, including 11,643 sepsis cases, and validated the findings across two large international cohorts. Results demonstrate that each standard deviation increase in plasma apoA-I levels reduces the incidence of sepsis by 13% and 28-day mortality by 27%.<\/p>\n

\nUsing Mendelian randomization<\/i>, the researchers confirmed that this protective effect is causal and independent<\/b> of other lipid fractions (HDL-C, LDL-C, triglycerides).<\/p>\n

\nMechanistically, higher apoA-I levels were linked to a reduction in circulating endotoxin (LPS)<\/b> levels, reinforcing apoA-I\u2019s role as a central modulator of inflammatory response and innate immunity in sepsis.<\/p>\n

\n\u201cThis publication is a game-changer,\u201d<\/i> said Dr. Rob SCOTT, MD, Head of R&D and CMO of ABIONYX Pharma. \u201cFor decades, the field of sepsis has searched for a causal target. The mechanistic effect of apoA-I and HDL has been well documented over the last 40 years but now, this new genetic validation provides proof that apoA-I is a major factor determining whether patients develop sepsis and whether they survive it.<\/i><\/p>\n

\nThis major publication in Nature<\/i> is a significant milestone that reinforces the scientific and strategic value of the company in ongoing discussions with a leading partner in sepsis.<\/p>\n

Contacts<\/b> <\/p>\n

\nABIONYX Pharma<\/b>
infos@abionyx.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

A Global Turning Point for Critical Care Medicine TOULOUSE, France & FULLERTON, Calif.–(BUSINESS WIRE)–ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the world’s only recombinant apoA-I, today announced the publication of a ground breaking study in Scientific Reports in Nature Portfolio titled \u201cPlasma apolipoprotein A-I is a … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62064","6":"format-standard","7":"category-industry"},"yoast_head":"\nABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"A Global Turning Point for Critical Care Medicine TOULOUSE, France & FULLERTON, Calif.–(BUSINESS WIRE)–ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the world’s only recombinant apoA-I, today announced the publication of a ground breaking study in Scientific Reports in Nature Portfolio titled \u201cPlasma apolipoprotein A-I is a ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-21T17:06:19+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis\",\"datePublished\":\"2025-10-21T17:06:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\\\/\"},\"wordCount\":410,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\\\/\",\"name\":\"ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2025-10-21T17:06:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\/","og_locale":"en_US","og_type":"article","og_title":"ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis - Pharma Trend","og_description":"A Global Turning Point for Critical Care Medicine TOULOUSE, France & FULLERTON, Calif.–(BUSINESS WIRE)–ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the world’s only recombinant apoA-I, today announced the publication of a ground breaking study in Scientific Reports in Nature Portfolio titled \u201cPlasma apolipoprotein A-I is a ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\/","og_site_name":"Pharma Trend","article_published_time":"2025-10-21T17:06:19+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis","datePublished":"2025-10-21T17:06:19+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\/"},"wordCount":410,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\/","url":"https:\/\/pharma-trend.com\/en\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\/","name":"ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2025-10-21T17:06:19+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/abionyx-pharma-announces-landmark-validation-a-study-published-in-nature-confirms-genetic-causality-of-apolipoprotein-a-i-apoa-i-in-sepsis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62064","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62064"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62064\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62064"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62064"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62064"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}